Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

EpiSwitch™ captures the heterogeneity of the environment on the genome.

Our Publications on Episwitch™


Validation of a new Epigenetic-based Prognostic Blood test to predict Prostate Cancer Aggressiveness

Pchejetski, D, et. al.,
Annals of Oncology
http://doi:10.1093/annonc/mdt459.36

Development of novel ALS treatment on the basis of mechanisms of cellular chronological life span control.

Youdell, M., et.al.,
12th Annual Northeast Amyotrophic Lateral Sclerosis Consortium
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALS-POSTER.pdf

A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Tan, Y., et. al.,
J Clinical Oncology
http://meetinglibrary.asco.org/content/113789-132

A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.

Petrie, K., et. al.,
Cancer Research
http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-87

Breast cancer: development of early non-invasive diagnostics to reduce disease mortality and psychological outcomes.

Jeznach, M., et.al.,
Psychoonkologia
http://www.termedia.pl/Breast-cancer-development-of-early-non-invasive-diagnostics-to-reduce-disease-mortality-and-psychological-outcomes,63,21815,0,1.html